Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

CTMX

CytomX Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1501989Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$76.0M
Net Income FY2025
$(17.0M)
EPS (Basic, as reported)
—
Net Margin FY2025
-22.8%
ROE FY2025
-17.5%
Total Equity
$99.0M
Shares Out
218M
Business description

CytomX Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2013–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 13 → 76 +21.7% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024⚑FY2025
Revenue13726057100705310113876
Research & development(55)(92)(104)(132)(113)(114)(112)(78)(83)(69)
General & administrative(20)(26)(34)(37)(36)(39)(43)(30)(30)(30)
Total operating expenses(75)(118)(137)(168)(149)(153)(154)(108)(113)(99)
Operating income(60)(46)(78)(111)(49)(84)(101)(6)25(22)
Interest expense(2)—————————
Interest & investment income23882021075
Other income (expense), net0000000000
Pre-tax income(59)(44)(70)(103)(47)(84)(99)332(17)
Income tax expense0(1)(14)0(14)00(4)00
Net income(59)(43)(85)(102)(33)(84)(99)(1)32(17)
Shares outstanding — basic (M)———454664667484138
Shares outstanding — diluted (M)———454664667485138

Showing the latest 10 of 13 fiscal years.

  • ⚑ Weighted-average shares changed ×1.64 between FY2024 and FY2025 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.